Koninklijke Philips N.V.
HealthcareNYSE:PHG · New York Stock Exchange
+$0.35 today
Vol 0.99M · Avg 1.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
8.2%
avg 6.2%
ROIC
5.3%
avg 1.5%
ROA
3.3%
avg 2.8%
Analysis
ROE is currently the strongest return metric at 8.2% versus its period average of 6.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Roy Jakobs | President, Chief Executive Officer & Chairman of the Board of Management | $3.69M | — | 52 | — | — |
Charlotte Hanneman | Executive Vice President, Chief Financial Officer & Member of Board of Management | $1.92M | — | 48 | — | — |
Marnix J. van Ginneken | Executive Vice President, Chief ESG & Legal Officer and Member of the Board of Management | $1.85M | — | 53 | — | — |
Paulus A. Stoffels | Independent Vice Chairman of Supervisory Board & Secretary | $213,864.00 | — | 64 | — | — |
Henk Siebren de Jong | Executive Vice President & Chief Executive Officer of Domestic Appliances | — | — | 62 | — | — |
Heidi Sichien | Executive Vice President & Chief People Officer | — | — | 52 | — | — |
Pim Preesman | Country Leader/ Health Systems Leader Indonesia | — | — | — | — | — |
Willem Appelo | Executive Vice President & Chief Operating Officer | — | — | 62 | — | — |
Durga Doraisamy | Head of Investor Relations | — | — | — | — | — |
Jan Kimpen | Chief Medical Officer | — | — | 68 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +42.1% | +8.4% (15yr)1 analysts |
| Revenue | N/A | N/A | -0.7% | -0.8% (15yr)5 analysts |
| Net Income | N/A | N/A | +41.8% | +8.3% (15yr)5 analysts |
| EBIT | N/A | N/A | -1.2% | +9.2% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +42.1% over three years. Forward estimates point to EBIT at +9.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$40.32B
Natera, Inc.
NASDAQ:NTRA
$30.37B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
BioNTech SE
NASDAQ:BNTX
$22.90B
Mettler-Toledo International Inc.
NYSE:MTD
$22.86B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
STERIS plc
NYSE:STE
$20.26B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Smith & Nephew plc
NYSE:SNN
$12.97B
Insulet Corporation
NASDAQ:PODD
$10.37B
Who manages PHG?
Koninklijke Philips N.V. (PHG) lists 10 active executives. The top listed executive is Paulus A. Stoffels, Independent Vice Chairman of Supervisory Board & Secretary.
Explore More
Continue the stock analysis
Jump to another research area for this company.